摘要
[目的]探讨程序性死亡蛋白1(PD-1)单抗联合微波消融治疗原发性肝癌的临床疗效.[方法]回顾性分析2019年1月至2020年10月本院收治的78例原发性肝癌患者的临床资料,根据治疗方法的不同将其分为联合组(予以PD-1单抗联合微波消融治疗)和对照组(单一微波消融治疗),每组39例.比较两组患者的临床疗效、免疫功能、不良反应,采用Kaplan-M eier分析患者生存率.[结果]联合组疾病控制率及客观缓解率均高于对照组,差异有统计学意义(P<0.05).治疗后,两组患者CD39^(+)、CD73^(+)水平均低于治疗前,且联合组均低于对照组(P<0.05).联合组皮疹发生率高于对照组,差异有统计学意义(P<0.05);两组其他不良反应发生情况比较,差异无统计学意义(P>0.05).两组总生存率曲线比较,差异有统计学意义(P<0.05).[结论]PD-1单抗联合微波热消融治疗原发性肝癌患者,有助于提高患者疾病控制率,延长患者生存期且具有一定的安全性.
【Objective】To investigate the clinical efficacy of programmed death protein 1(PD-1)monoclonal antibody combined with microwave ablation in the treatment of primary liver cancer.【Methods】The clinical data of 78 patients with primary liver cancer admitted to our hospital from January 2019 to October 2020 were analyzed retrospectively.According to the different treatment methods,they were divided into combined group(treated with PD-1 monoclonal antibody combined with microwave ablation)and control group(treated with single microwave ablation),with 39 patients in each group.The clinical efficacy,immune function and adverse reactions of the two groups were compared,and the survival rate was analyzed by Kaplan-Meier.【Results】The disease control rate and objective remission rate in the combined group were higher than those in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CD39^(+)and CD73^(+)in both groups were lower than those before treatment,and those in the combined group were lower than those in the control group(P<0.05).The incidence of rash in the combined group was higher than that in the control group(P<0.05);There was no statistically significant difference in the occurrence of other adverse reactions between the two groups(P>0.05).The difference between the two groups was statistically significant(P<0.05).【Conclusion】PD-1 monoclonal antibody combined with microwave thermal ablation is helpful to improve the disease control rate and prolong the survival time of patients with primary liver cancer,and has certain safety.
作者
侯龙辉
韦杨超
HOU Long-hui;WEI Yang-chao(Baoji General Hospital,Baoji Shaanxi 721000)
出处
《医学临床研究》
CAS
2023年第1期95-97,101,共4页
Journal of Clinical Research
